Abiomed gets Impella pump EUA for coronavirus-related heart failure

Blood clots of various types have been associated with the novel coronavirus, especially in critically ill patients. Abiomed says clinicians have been using the system to treat COVID-19 patients with acute clots causing a backup of blood in the heart chambers. (Getty Images)

The FDA granted an emergency authorization to Abiomed’s Impella RP heart pump system for COVID-19 patients suffering from right-sided heart failure, including those with a pulmonary embolism.

Blood clots of various sizes, types and locations within the body have been associated with the novel coronavirus infection, especially in the most critically ill patients. 

The Impella system is a temporary, catheter-based heart pump that picks up blood from the vena cava just outside the heart and conveys it through the right atrium and ventricle through a tube into the pulmonary artery, pushing it toward the lungs. 

Sponsored by Clinical Ink

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Ink’s intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.
The Impella RP system (Abiomed)

This lessens the overall load on the heart muscle and is designed to help patients recover in the days following a heart attack, transplant or open surgery as well as those who have received device implants in the left side of their heart. The device was first approved by the FDA in 2017. 

RELATED: Abiomed gets FDA nod for revised Impella heart pump

According to Abiomed, clinicians have been using the system to treat certain COVID-19 patients with acute blood clots within the pulmonary artery, causing a backup that leads to right ventricular heart failure. 

Using minimally invasive techniques, the Impella pump can be deployed quickly in either a catheterization lab or an operating room after the clot has been removed, the company said.

Suggested Articles

The FDA cleared a miniaturized and disposable sensor patch designed to detect early complications from IV drug infusions.

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Philips announced plans to integrate BioIntelliSense’s health-tracking sticker into its remote patient monitoring programs.